Gilead Sciences, Inc. (NASDAQ:GILD), the undisputed leader of the fast-expanding hepatitis C treatment market, will continue to see strong growth from its top-selling franchise despite a stagnating trend in the industry. The upcoming pan-genotype HCV drug of the biotech giant is expected to play a key role in buoying HCV sales of the company thus safeguarding the leading share it holds in Hepatitis C market.
